Stoke Therapeutics, Inc. (STOK) 10-Year Financial Performance & Capital Metrics

STOK •

HealthcareBiotechnologyRNA and Genome Editing Developers

AboutStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Show more

Revenue $37M +316.3%
EBITDA -$99M +11.7%
Net Income -$89M +15.0%
EPS (Diluted) -1.65 +30.7%
Gross Margin 100%
EBITDA Margin -271.36% +78.8%
Operating Margin -277.31% +78.8%
Net Margin -243.42% +79.6%
ROE -45.8% +24.7%
ROIC -206.76% +47.4%
Debt/Equity 0.01 -21.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 93 (top 7%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 22.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM1128.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM138.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM131.9%

ROCE

10Y Avg-35.61%

5Y Avg-40.6%

3Y Avg-49.46%

Latest-47.26%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	12.4M	8.78M	36.55M
Revenue Growth %	-	-	-	-	-	-	-29.22%	316.34%
Cost of Goods Sold+	113K	214K	450K	1.93M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-113K	-214K	-450K	-1.93M	0	12.4M	8.78M	36.55M
Gross Margin %	-	-	-	-	-	100%	100%	100%
Gross Profit Growth %	-	-89.38%	-110.28%	-328%	100%	-	-29.22%	316.34%
Operating Expenses+	5.55M	12.78M	35.23M	51.12M	86.06M	116.76M	123.55M	137.93M
OpEx % of Revenue	-	-	-	-	-	941.24%	1407.21%	377.31%
Selling, General & Admin	1.96M	4.41M	11.91M	20.85M	31.9M	38.92M	41.32M	48.79M
SG&A % of Revenue	-	-	-	-	-	313.78%	470.64%	133.48%
Research & Development	3.6M	8.37M	23.31M	32.2M	54.17M	77.84M	82.23M	89.13M
R&D % of Revenue	-	-	-	-	-	627.46%	936.57%	243.83%
Other Operating Expenses	-4K	-10K	0	-1.93M	0	0	0	0
Operating Income+	-5.55M	-12.78M	-35.68M	-53.04M	-86.06M	-104.36M	-114.77M	-101.37M
Operating Margin %	-	-	-	-	-	-841.24%	-1307.21%	-277.31%
Operating Income Growth %	-	-130.12%	-179.15%	-48.67%	-62.25%	-21.25%	-9.98%	11.68%
EBITDA+	-5.44M	-12.57M	-35.23M	-51.12M	-85.09M	-102.81M	-112.3M	-99.19M
EBITDA Margin %	-	-	-	-	-	-828.78%	-1279.09%	-271.36%
EBITDA Growth %	-	-130.97%	-180.32%	-45.11%	-66.46%	-20.82%	-9.23%	11.67%
D&A (Non-Cash Add-back)	113K	214K	450K	1.93M	974K	1.55M	2.47M	2.18M
EBIT	-5.55M	-12.78M	-32.33M	-52.24M	-86.06M	-104.36M	-114.77M	-101.37M
Net Interest Income+	0	0	3.35M	744K	120K	0	0	0
Interest Income	0	270K	3.35M	744K	120K	0	0	0
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	-4K	260K	3.35M	801K	260K	3.29M	10.07M	12.39M
Pretax Income+	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Pretax Margin %	-	-	-	-	-	-814.73%	-1192.47%	-243.42%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Net Margin %	-	-	-	-	-	-814.73%	-1192.47%	-243.42%
Net Income Growth %	-	-125.28%	-158.17%	-61.62%	-64.24%	-17.79%	-3.59%	15.01%
Net Income (Continuing)	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.24	-0.53	-1.59	-1.56	-2.34	-2.60	-2.38	-1.65
EPS Growth %	-	-120.83%	-200%	1.89%	-50%	-11.11%	8.46%	30.67%
EPS (Basic)	-0.24	-0.53	-1.59	-1.56	-2.34	-2.60	-2.38	-1.65
Diluted Shares Outstanding	23.51M	23.51M	17.97M	33.49M	36.74M	38.9M	43.99M	54.01M
Basic Shares Outstanding	23.51M	23.51M	17.97M	33.49M	36.74M	38.9M	43.99M	54.01M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.91M	106.14M	226.03M	293.93M	229.22M	244.07M	215.34M	232.76M
Cash & Short-Term Investments	1.8M	105.4M	222.47M	287.31M	219.81M	229.59M	201.39M	216.9M
Cash Only	1.8M	105.4M	222.47M	287.31M	144.9M	113.56M	191.44M	127.98M
Short-Term Investments	0	0	0	0	74.92M	116.04M	9.95M	88.92M
Accounts Receivable	0	196K	281K	6K	132K	588K	64K	700K
Days Sales Outstanding	-	-	-	-	-	17.3	2.66	6.99
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	181K	2.33M	2.96M	2.56M	4.04M
Total Non-Current Assets+	529K	1.4M	2.72M	4M	9.65M	12M	13M	38.8M
Property, Plant & Equipment	473K	1.19M	2.51M	3.79M	9.08M	11.43M	12.43M	8.25M
Fixed Asset Turnover	-	-	-	-	-	1.09x	0.71x	4.43x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	56K	204K	0	0	0	0	0	29.82M
Other Non-Current Assets	0	0	205K	205K	569K	569K	569K	721K
Total Assets+	2.44M	107.54M	228.75M	297.93M	238.87M	256.07M	228.34M	271.56M
Asset Turnover	-	-	-	-	-	0.05x	0.04x	0.13x
Asset Growth %	-	4309.14%	112.71%	30.24%	-19.82%	7.2%	-10.83%	18.92%
Total Current Liabilities+	3.71M	2.47M	4.1M	11.43M	17.14M	31.39M	30.82M	40.06M
Accounts Payable	141K	1.07M	751K	1.5M	2.38M	766K	1.7M	2.5M
Days Payables Outstanding	455.44	1.83K	609.14	283.32	-	-	-	-
Short-Term Debt	3M	0	0	0	0	0	0	0
Deferred Revenue (Current)	-3M	0	0	0	0	14.88M	15.31M	18.99M
Other Current Liabilities	0	0	2.11M	4.58M	5.92M	6.26M	6.47M	8.44M
Current Ratio	0.51x	43.03x	55.12x	25.73x	13.37x	7.77x	6.99x	5.81x
Quick Ratio	0.51x	43.03x	55.12x	25.73x	13.37x	7.77x	6.99x	5.81x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	16K	4K	221K	422K	3.95M	39.82M	37.96M	2.48M
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	16K	4K	221K	422K	3.95M	2.97M	4.88M	2.48M
Total Liabilities	3.73M	2.47M	4.32M	11.85M	21.09M	71.22M	68.78M	42.53M
Total Debt+	3M	0	0	1.07M	1.51M	2.36M	2.06M	2.32M
Net Debt	1.2M	-105.4M	-222.47M	-286.24M	-143.39M	-111.2M	-189.38M	-125.66M
Debt / Equity	-	-	-	0.00x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-1.29M	105.07M	224.43M	286.08M	217.78M	184.85M	159.56M	229.02M
Equity Growth %	-	8232.2%	113.6%	27.47%	-23.88%	-15.12%	-13.68%	43.53%
Book Value per Share	-0.05	4.47	12.49	8.54	5.93	4.75	3.63	4.24
Total Shareholders' Equity	-1.29M	105.07M	224.43M	286.08M	217.78M	184.85M	159.56M	229.02M
Common Stock	1K	1K	3K	4K	4K	4K	5K	5K
Retained Earnings	-13.19M	-25.71M	-58.03M	-110.28M	-196.08M	-297.15M	-401.85M	-490.83M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-172K	-379K	0	0	-168K	-1.18M	-24K	-151K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.38M	-10.96M	-31.05M	-42.22M	-66.91M	-31.87M	-81.07M	-86.85M
Operating CF Margin %	-	-	-	-	-	-256.88%	-923.31%	-237.59%
Operating CF Growth %	-	-103.64%	-183.25%	-35.96%	-58.47%	52.37%	-154.4%	-7.13%
Net Income	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Depreciation & Amortization	113K	214K	450K	888K	974K	1.55M	2.47M	2.18M
Stock-Based Compensation	26K	240K	1.92M	5.77M	16.45M	22.85M	25.26M	27.47M
Deferred Taxes	0	0	0	3K	172K	0	0	0
Other Non-Cash Items	4K	10K	3K	1.04M	1.26M	1.78M	1.94M	623K
Working Capital Changes	31K	1.09M	-1.1M	2.33M	46K	43.02M	-6.03M	-28.14M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	100K	1.74M	891K	5.2M	2.9M	121K	-3.21M	3.09M
Cash from Investing+	-113K	-925K	-1.63M	-1.05M	-76.43M	-45.88M	105.95M	-107.47M
Capital Expenditures	-113K	-935K	-1.64M	-1.05M	-1.2M	-3.96M	-1.62M	-203K
CapEx % of Revenue	-	-	-	-	-	31.94%	18.41%	0.56%
Acquisitions	0	10K	1K	0	75.23M	45.34M	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	10K	0	0	-75.23M	-45.34M	0	0
Cash from Financing+	5.97M	115.64M	149.76M	108.11M	1.28M	46.41M	53.01M	131.09M
Debt Issued (Net)	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	2.97M	-361K	-2.15M	2.71M	-2K	1.06M	926K	2.25M
Net Change in Cash	477K	103.75M	117.07M	64.84M	-142.05M	-31.34M	77.89M	-63.23M
Free Cash Flow+	-5.5M	-11.9M	-32.69M	-43.27M	-68.11M	-35.83M	-82.68M	-87.05M
FCF Margin %	-	-	-	-	-	-288.82%	-941.72%	-238.15%
FCF Growth %	-	-116.46%	-174.73%	-32.37%	-57.4%	47.39%	-130.78%	-5.29%
FCF per Share	-0.23	-0.51	-1.82	-1.29	-1.85	-0.92	-1.88	-1.61
FCF Conversion (FCF/Net Income)	0.97x	0.88x	0.96x	0.81x	0.78x	0.32x	0.77x	0.98x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-24.13%	-19.62%	-20.47%	-34.06%	-50.2%	-60.8%	-45.8%
Return on Invested Capital (ROIC)	-	-	-3291.33%	-4437.59%	-173.93%	-105.74%	-392.73%	-206.76%
Gross Margin	-	-	-	-	-	100%	100%	100%
Net Margin	-	-	-	-	-	-814.73%	-1192.47%	-243.42%
Debt / Equity	-	-	-	0.00x	0.01x	0.01x	0.01x	0.01x
FCF Conversion	0.97x	0.88x	0.96x	0.81x	0.78x	0.32x	0.77x	0.98x
Revenue Growth	-	-	-	-	-	-	-29.22%	316.34%

US Stock Screener

...

Stoke Therapeutics, Inc. (STOK) 10-Year Financial Performance & Capital Metrics

STOK •

HealthcareBiotechnologyRNA and Genome Editing Developers

Revenue $37M +316.3%
EBITDA -$99M +11.7%
Net Income -$89M +15.0%
EPS (Diluted) -1.65 +30.7%
Gross Margin 100%
EBITDA Margin -271.36% +78.8%
Operating Margin -277.31% +78.8%
Net Margin -243.42% +79.6%
ROE -45.8% +24.7%
ROIC -206.76% +47.4%
Debt/Equity 0.01 -21.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 93 (top 7%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 22.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM1128.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM138.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM131.9%

ROCE

10Y Avg-35.61%

5Y Avg-40.6%

3Y Avg-49.46%

Latest-47.26%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	12.4M	8.78M	36.55M
Revenue Growth %	-	-	-	-	-	-	-29.22%	316.34%
Cost of Goods Sold+	113K	214K	450K	1.93M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-113K	-214K	-450K	-1.93M	0	12.4M	8.78M	36.55M
Gross Margin %	-	-	-	-	-	100%	100%	100%
Gross Profit Growth %	-	-89.38%	-110.28%	-328%	100%	-	-29.22%	316.34%
Operating Expenses+	5.55M	12.78M	35.23M	51.12M	86.06M	116.76M	123.55M	137.93M
OpEx % of Revenue	-	-	-	-	-	941.24%	1407.21%	377.31%
Selling, General & Admin	1.96M	4.41M	11.91M	20.85M	31.9M	38.92M	41.32M	48.79M
SG&A % of Revenue	-	-	-	-	-	313.78%	470.64%	133.48%
Research & Development	3.6M	8.37M	23.31M	32.2M	54.17M	77.84M	82.23M	89.13M
R&D % of Revenue	-	-	-	-	-	627.46%	936.57%	243.83%
Other Operating Expenses	-4K	-10K	0	-1.93M	0	0	0	0
Operating Income+	-5.55M	-12.78M	-35.68M	-53.04M	-86.06M	-104.36M	-114.77M	-101.37M
Operating Margin %	-	-	-	-	-	-841.24%	-1307.21%	-277.31%
Operating Income Growth %	-	-130.12%	-179.15%	-48.67%	-62.25%	-21.25%	-9.98%	11.68%
EBITDA+	-5.44M	-12.57M	-35.23M	-51.12M	-85.09M	-102.81M	-112.3M	-99.19M
EBITDA Margin %	-	-	-	-	-	-828.78%	-1279.09%	-271.36%
EBITDA Growth %	-	-130.97%	-180.32%	-45.11%	-66.46%	-20.82%	-9.23%	11.67%
D&A (Non-Cash Add-back)	113K	214K	450K	1.93M	974K	1.55M	2.47M	2.18M
EBIT	-5.55M	-12.78M	-32.33M	-52.24M	-86.06M	-104.36M	-114.77M	-101.37M
Net Interest Income+	0	0	3.35M	744K	120K	0	0	0
Interest Income	0	270K	3.35M	744K	120K	0	0	0
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	-4K	260K	3.35M	801K	260K	3.29M	10.07M	12.39M
Pretax Income+	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Pretax Margin %	-	-	-	-	-	-814.73%	-1192.47%	-243.42%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Net Margin %	-	-	-	-	-	-814.73%	-1192.47%	-243.42%
Net Income Growth %	-	-125.28%	-158.17%	-61.62%	-64.24%	-17.79%	-3.59%	15.01%
Net Income (Continuing)	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.24	-0.53	-1.59	-1.56	-2.34	-2.60	-2.38	-1.65
EPS Growth %	-	-120.83%	-200%	1.89%	-50%	-11.11%	8.46%	30.67%
EPS (Basic)	-0.24	-0.53	-1.59	-1.56	-2.34	-2.60	-2.38	-1.65
Diluted Shares Outstanding	23.51M	23.51M	17.97M	33.49M	36.74M	38.9M	43.99M	54.01M
Basic Shares Outstanding	23.51M	23.51M	17.97M	33.49M	36.74M	38.9M	43.99M	54.01M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.91M	106.14M	226.03M	293.93M	229.22M	244.07M	215.34M	232.76M
Cash & Short-Term Investments	1.8M	105.4M	222.47M	287.31M	219.81M	229.59M	201.39M	216.9M
Cash Only	1.8M	105.4M	222.47M	287.31M	144.9M	113.56M	191.44M	127.98M
Short-Term Investments	0	0	0	0	74.92M	116.04M	9.95M	88.92M
Accounts Receivable	0	196K	281K	6K	132K	588K	64K	700K
Days Sales Outstanding	-	-	-	-	-	17.3	2.66	6.99
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	181K	2.33M	2.96M	2.56M	4.04M
Total Non-Current Assets+	529K	1.4M	2.72M	4M	9.65M	12M	13M	38.8M
Property, Plant & Equipment	473K	1.19M	2.51M	3.79M	9.08M	11.43M	12.43M	8.25M
Fixed Asset Turnover	-	-	-	-	-	1.09x	0.71x	4.43x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	56K	204K	0	0	0	0	0	29.82M
Other Non-Current Assets	0	0	205K	205K	569K	569K	569K	721K
Total Assets+	2.44M	107.54M	228.75M	297.93M	238.87M	256.07M	228.34M	271.56M
Asset Turnover	-	-	-	-	-	0.05x	0.04x	0.13x
Asset Growth %	-	4309.14%	112.71%	30.24%	-19.82%	7.2%	-10.83%	18.92%
Total Current Liabilities+	3.71M	2.47M	4.1M	11.43M	17.14M	31.39M	30.82M	40.06M
Accounts Payable	141K	1.07M	751K	1.5M	2.38M	766K	1.7M	2.5M
Days Payables Outstanding	455.44	1.83K	609.14	283.32	-	-	-	-
Short-Term Debt	3M	0	0	0	0	0	0	0
Deferred Revenue (Current)	-3M	0	0	0	0	14.88M	15.31M	18.99M
Other Current Liabilities	0	0	2.11M	4.58M	5.92M	6.26M	6.47M	8.44M
Current Ratio	0.51x	43.03x	55.12x	25.73x	13.37x	7.77x	6.99x	5.81x
Quick Ratio	0.51x	43.03x	55.12x	25.73x	13.37x	7.77x	6.99x	5.81x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	16K	4K	221K	422K	3.95M	39.82M	37.96M	2.48M
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	16K	4K	221K	422K	3.95M	2.97M	4.88M	2.48M
Total Liabilities	3.73M	2.47M	4.32M	11.85M	21.09M	71.22M	68.78M	42.53M
Total Debt+	3M	0	0	1.07M	1.51M	2.36M	2.06M	2.32M
Net Debt	1.2M	-105.4M	-222.47M	-286.24M	-143.39M	-111.2M	-189.38M	-125.66M
Debt / Equity	-	-	-	0.00x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-1.29M	105.07M	224.43M	286.08M	217.78M	184.85M	159.56M	229.02M
Equity Growth %	-	8232.2%	113.6%	27.47%	-23.88%	-15.12%	-13.68%	43.53%
Book Value per Share	-0.05	4.47	12.49	8.54	5.93	4.75	3.63	4.24
Total Shareholders' Equity	-1.29M	105.07M	224.43M	286.08M	217.78M	184.85M	159.56M	229.02M
Common Stock	1K	1K	3K	4K	4K	4K	5K	5K
Retained Earnings	-13.19M	-25.71M	-58.03M	-110.28M	-196.08M	-297.15M	-401.85M	-490.83M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-172K	-379K	0	0	-168K	-1.18M	-24K	-151K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.38M	-10.96M	-31.05M	-42.22M	-66.91M	-31.87M	-81.07M	-86.85M
Operating CF Margin %	-	-	-	-	-	-256.88%	-923.31%	-237.59%
Operating CF Growth %	-	-103.64%	-183.25%	-35.96%	-58.47%	52.37%	-154.4%	-7.13%
Net Income	-5.56M	-12.52M	-32.33M	-52.24M	-85.81M	-101.07M	-104.7M	-88.98M
Depreciation & Amortization	113K	214K	450K	888K	974K	1.55M	2.47M	2.18M
Stock-Based Compensation	26K	240K	1.92M	5.77M	16.45M	22.85M	25.26M	27.47M
Deferred Taxes	0	0	0	3K	172K	0	0	0
Other Non-Cash Items	4K	10K	3K	1.04M	1.26M	1.78M	1.94M	623K
Working Capital Changes	31K	1.09M	-1.1M	2.33M	46K	43.02M	-6.03M	-28.14M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	100K	1.74M	891K	5.2M	2.9M	121K	-3.21M	3.09M
Cash from Investing+	-113K	-925K	-1.63M	-1.05M	-76.43M	-45.88M	105.95M	-107.47M
Capital Expenditures	-113K	-935K	-1.64M	-1.05M	-1.2M	-3.96M	-1.62M	-203K
CapEx % of Revenue	-	-	-	-	-	31.94%	18.41%	0.56%
Acquisitions	0	10K	1K	0	75.23M	45.34M	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	10K	0	0	-75.23M	-45.34M	0	0
Cash from Financing+	5.97M	115.64M	149.76M	108.11M	1.28M	46.41M	53.01M	131.09M
Debt Issued (Net)	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	2.97M	-361K	-2.15M	2.71M	-2K	1.06M	926K	2.25M
Net Change in Cash	477K	103.75M	117.07M	64.84M	-142.05M	-31.34M	77.89M	-63.23M
Free Cash Flow+	-5.5M	-11.9M	-32.69M	-43.27M	-68.11M	-35.83M	-82.68M	-87.05M
FCF Margin %	-	-	-	-	-	-288.82%	-941.72%	-238.15%
FCF Growth %	-	-116.46%	-174.73%	-32.37%	-57.4%	47.39%	-130.78%	-5.29%
FCF per Share	-0.23	-0.51	-1.82	-1.29	-1.85	-0.92	-1.88	-1.61
FCF Conversion (FCF/Net Income)	0.97x	0.88x	0.96x	0.81x	0.78x	0.32x	0.77x	0.98x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-24.13%	-19.62%	-20.47%	-34.06%	-50.2%	-60.8%	-45.8%
Return on Invested Capital (ROIC)	-	-	-3291.33%	-4437.59%	-173.93%	-105.74%	-392.73%	-206.76%
Gross Margin	-	-	-	-	-	100%	100%	100%
Net Margin	-	-	-	-	-	-814.73%	-1192.47%	-243.42%
Debt / Equity	-	-	-	0.00x	0.01x	0.01x	0.01x	0.01x
FCF Conversion	0.97x	0.88x	0.96x	0.81x	0.78x	0.32x	0.77x	0.98x
Revenue Growth	-	-	-	-	-	-	-29.22%	316.34%

Stoke Therapeutics, Inc. (STOK) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare STOK vs Peers

vs ALNY

vs IONS

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Stoke Therapeutics, Inc. (STOK) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare STOK vs Peers

vs ALNY

vs IONS

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios